ResultsHealthcare & Life Sciences
Tata 1mg revenue FY26: Rs 2,936 Cr, net loss Rs 287 Cr
Tata 1mg revenue nears Rs 3,000 Cr with narrowing loss
By Abha Lohia · Editor ·
Tata 1mg revenue
Tata 1mg reported revenue of Rs 2,936 Cr in FY26, with a net loss of Rs 287 Cr, as reported by Entrackr on 28 July 2026.
| Revenue (FY26) | Rs 2,936 Cr |
|---|---|
| Net loss (FY26) | Rs 287 Cr |
Tata 1mg: revenue and funding and every story →
- Tata 1mg is a digital healthcare platform selling medicines and diagnostics online
- FY26 revenue reached Rs 2,936 Cr while net loss narrowed to Rs 287 Cr
- The company faces competition from Netmeds, PharmEasy, and Apollo 24/7 in the market
What happened
- Tata 1mg reported FY26 consolidated revenue of Rs 2,936 Cr, up 23% from FY25.
- The company's net loss narrowed to Rs 287 Cr for the fiscal year 2026.
- Revenue split showed Rs 2,440 Cr from Healthcare Solutions and Rs 496 Cr from Technologies.
- Tata 1mg Healthcare Solutions posted a loss of Rs 310 Cr during the period.
- Tata 1mg Technologies contributed a profit of Rs 23 Cr to the combined results.
- Total assets stood at Rs 2,268 Cr with liabilities totaling Rs 1,601 Cr.
- Reserves remained negative at Rs 167 Cr due to significant losses in the healthcare entity.
- Tata Digital acquired a majority stake in 1mg in June 2021 to expand its ecosystem.
Why it matters
- Tata Digital group revenue grew 12% to Rs 35,990 Cr in FY26.
- The parent group's net loss widened to Rs 4,974 Cr from the previous year.
- Tata Digital GMV reached Rs 46,515 Cr indicating strong transaction volumes across sectors.
The business
- The platform sells allopathic, ayurvedic, and homeopathic medicines through its online store.
- It offers vitamins, nutrition supplements, and general healthcare products to consumers.
- Diagnostics services form a key part of its healthcare service offerings.
- The company operates under two entities: Healthcare Solutions and Technologies.
- Healthcare Solutions drives the majority of revenue and asset base.
- Technologies contributes smaller revenue but remains profitable independently.
- The business model relies on digital distribution of medical products.
- It competes directly with other major online pharmacy players in India.
In numbers
Rs 2,936 CrConsolidated Revenue · FY26
Rs 287 CrNet Loss · FY26
Rs 2,440 CrHealthcare Solutions Revenue · FY26
Rs 23 CrTechnologies Profit · FY26
Rs 2,268 CrTotal Assets · FY26
Up against
Reliance-backed NetmedsPharmEasyApollo 24/7
The numbers around it
Healthcare & Life Sciences in July 2026: 11 rounds with a disclosed amount, $87.1 million in all; the biggest was Iswarya (Rs 350 crore). Every sector this year →
Terms in this story
- Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on Tata 1mg → · All startup news on 28 July 2026 →
Is this Tata 1mg? Get your “Featured on StopDown” badge →